Updated migraine prevention guidance incorporates calcitonin gene-related peptide (CGRP)-targeted therapies and places greater emphasis on individualized treatment selection based on patient priorities.
Preventive therapy should be offered to those with at least 4 migraine days per month, at least 4 moderate-to-severe headache days per month, or substantial migraine-related disability.
We are pleased to welcome genedrive as a sponsor and exhibitor at this year’s GIANT Health Event.
Based in Manchester, genedrive is a diagnostics company developing rapid pharmacogenetic testing solutions designed to support safer, more effective prescribing decisions. By helping…
As healthcare systems continue to evolve, ensuring that new technologies deliver real value for patients, professionals, and the wider health and care system is more important than ever.
At GIANT Health, we are pleased to highlight our exhibitor Health Technology…
Attendees
Sponsors and Exhibitors
Contact us